Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Ovarian Neoplasms 15Fallopian Tube Neoplasms 13Lung Neoplasms 11Melanoma 8Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Breast Neoplasms 4Brain Neoplasms 4Prostatic Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Uveal Melanoma 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Rectal Neoplasms 2Oligodendroglioma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma 2Liposarcoma 2Hematologic Neoplasms 2Gliosarcoma 2

Interventions

Doxorubicin 6Trabectedin 5pazopanib 4Radiotherapy 4ribociclib 3pembrolizumab 3palbociclib 3Gemcitabine 3brostallicin 2Sunitinib 2Radiation Dose Hypofractionation 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Immunoglobulin G 2Imatinib Mesylate 2Ifosfamide 2Docetaxel 2Dexamethasone 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zimberelimab 1temsirolimus 1tanespimycin 1talimogene laherparepvec 1sotigalimab 1soblidotin 1sitravatinib 1saracatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Liposarcoma × Immunoglobulin G × Clear all
NCT05694871 2026-05-11

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
77 enrolled
Sarcoma

Liposarcoma

NCT04668300 2026-04-15

DOSa

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
75 enrolled
Sarcoma

Hemangiosarcoma, Liposarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡